Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Search

Page Path
HOME > Search
2 "Hepatitis C"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
IBD
Prevalence of hepatitis B virus and hepatitis C virus infection in patients with inflammatory bowel disease: a systematic review and meta-analysis
Suprabhat Giri, Dhiraj Agrawal, Shivaraj Afzalpurkar, Sunil Kasturi, Amrit Gopan, Sridhar Sundaram, Aditya Kale
Intest Res 2023;21(3):392-405.   Published online December 2, 2022
DOI: https://doi.org/10.5217/ir.2022.00094
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
The data on the prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in patients with inflammatory bowel disease (IBD) are conflicting. The present systematic review was thus conducted to study the prevalence of HBV and HCV markers in patients with IBD.
Methods
A comprehensive literature search of 3 databases was conducted from 2000 to April 2022 for studies evaluating the prevalence of HBV or HCV in patients with IBD. Pooled prevalence rates across studies were expressed with summative statistics.
Results
A total of 34 studies were included in the final analysis. The pooled prevalence of hepatitis B surface antigen (HBsAg) and hepatitis B core antibodies were 3.3% and 14.2%, respectively. In HBsAg positive IBD patients, hepatitis B e antigen positivity and detectable HBV DNA were seen in 15.3% and 61.0% of patients, respectively. Only 35.6% of the IBD patients had effective HBV vaccination. The pooled prevalence of anti-HCV and detectable HCV RNA were 1.8% and 0.8%, respectively. The pooled prevalence of markers of HBV infection was higher in Asian studies, while the prevalence of markers of HCV infection was higher in European studies. The prevalence of viral hepatitis markers was similar between IBD patients and the general population and that between ulcerative colitis and Crohn’s disease.
Conclusions
The prevalence of markers of viral hepatitis remains same as the general population with significant regional variations, although the quality of evidence remains low due to publication bias. Only a small proportion of IBD patients had an effective HBV vaccination, requiring improvement in screening and vaccination practices.

Citations

Citations to this article as recorded by  
  • Prevalence of Comorbidities in Inflammatory Bowel Disease: An Umbrella Review of 18 Systematic Reviews
    Lupita Ana Maria Valladolid-Sandoval, Jhosmer Ballena-Caicedo, Fiorella E. Zuzunaga-Montoya, Darwin A. León-Figueroa, Percy Ordemar Vásquez, Mario J. Valladares-Garrido, Víctor Juan Vera-Ponce
    Journal of Clinical Medicine.2026; 15(5): 1739.     CrossRef
  • ECCO consensus on management of inflammatory bowel disease in low- and middle-income countries
    Alaa El-Hussuna, Almuthe Christina Hauer, Tarkan Karakan, Valerie Pittet, Henit Yanai, Jalpa Devi, Jesus K Yamamoto-Furusho, Ali Reza Sima, Hailemichael Desalegn, Mutaz Idrees Sultan, Vishal Sharma, Hany Shehab, Lamya Mrabti, Natalia Queiroz, Anuraag Jena
    Journal of Crohn’s and Colitis.2026;[Epub]     CrossRef
  • Prevalence of viral hepatitis A and C in patients with inflammatory bowel disease: a nationwide population-based study in South Korea
    Jin Hwa Park, Sang Hyoung Park, Sang Pyo Lee, Kang Nyeong Lee, Hang Lak Lee, Oh Young Lee, Soorack Ryu, Junwon Go
    The Korean Journal of Internal Medicine.2026; 41(1): 95.     CrossRef
  • Hepatobiliary and pancreatic manifestations in inflammatory bowel disease: an umbrella review of meta-analyses
    Runsheng Hong, Zhixue Li, Meng Li, Yun Dai
    Therapeutic Advances in Gastroenterology.2025;[Epub]     CrossRef
  • Serological Assessment of Hepatitis in Patients with Inflammatory Bowel Disease in Taiwan: A Retrospective Cohort Analysis
    Yueh-An Lee, Hsu-Heng Yen, Yang-Yuan Chen
    Life.2025; 15(6): 893.     CrossRef
  • British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025
    Gordon W Moran, Morris Gordon, Vassiliki Sinopoulou, Shellie J Radford, Ana-Maria Darie, Sudheer Kumar Vuyyuru, Laith Alrubaiy, Naila Arebi, Jonathan Blackwell, Thomas D Butler, Thean Chew, Michael Colwill, Rachel Cooney, Gabriele De Marco, Said Din, Shah
    Gut.2025; 74(Suppl 2): s1.     CrossRef
  • Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023
    Hsu-Heng Yen, Jia-Feng Wu, Horng-Yuan Wang, Ting-An Chang, Chung-Hsin Chang, Chen-Wang Chang, Te-Hsin Chao, Jen-Wei Chou, Yenn-Hwei Chou, Chiao-Hsiung Chuang, Wen-Hung Hsu, Tzu-Chi Hsu, Tien-Yu Huang, Tsung-I Hung, Puo-Hsien Le, Chun-Che Lin, Chun-Chi Lin
    Intestinal Research.2024; 22(3): 213.     CrossRef
  • Assessing the associations of inflammatory bowel disease and hepatitis B virus infections with two-sample bidirectional mendelian randomization
    Ping Han, Chaohui Wang, Yan Qiu
    Critical Public Health.2024; 34(1): 1.     CrossRef
  • Associations between chronic hepatitis B infection and inflammatory bowel diseases in East Asian populations
    Haiyan Ye, Deqin Wei, Yike Huang
    Future Virology.2024; 19(16-18): 563.     CrossRef
  • Protective role of flavonoids quercetin and silymarin in the viral-associated inflammatory bowel disease: an updated review
    Elham Zarenezhad, Hussein T. Abdulabbas, Ahmed Shayaa Kareem, Seyed Amin Kouhpayeh, Silvia Barbaresi, Sohrab Najafipour, Abdulbaset Mazarzaei, Mitra Sotoudeh, Abdolmajid Ghasemian
    Archives of Microbiology.2023;[Epub]     CrossRef
  • Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
    Yu Kyung Jun, Seong-Joon Koh, Dae Seong Myung, Sang Hyoung Park, Choon Jin Ooi, Ajit Sood, Jong Pil Im
    Intestinal Research.2023; 21(3): 353.     CrossRef
  • Ulcerative colitis coexisting with hepatitis C: A rare occurrence
    Xiaoqiang Liu, Yisen Huan, Yubin Wang, Yingxuan Huang
    Medicine.2023; 102(50): e36629.     CrossRef
  • 8,425 View
  • 401 Download
  • 11 Web of Science
  • 12 Crossref
Close layer
Prevalence of hepatitis B, hepatitis C and human immunodeficiency viral infections in patients with inflammatory bowel disease in north India
Parnita Harsh, Vipin Gupta, Saurabh Kedia, Sawan Bopanna, Sucharita Pilli, Surendernath, Govind Kumar Makharia, Vineet Ahuja
Intest Res 2017;15(1):97-102.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.97
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Patients with inflammatory bowel disease (IBD) often require immunosuppressive therapy and blood transfusions and therefore are at a high risk of contracting infections due to hepatitis B (HBV) and hepatitis C (HCV) and human immunodeficiency virus (HIV). In the present study, we assessed the prevalence of these infections in patients with IBD.

Methods

This retrospective study included 908 consecutive patients with IBD (ulcerative colitis [UC], n=581; Crohn's disease [CD], n=327) who were receiving care at a tertiary care center. Ninety-five patients with intestinal tuberculosis (ITB) were recruited as disease controls. Prospectively maintained patient databases were reviewed for the prevalence of HBV surface antigen, anti-HCV antibodies, and HIV (enzyme-linked immunosorbent assay method). HCV RNA was examined in patients who tested positive for anti-HCV antibodies. Prevalence data of the study were compared with that of the general Indian population (HBV, 3.7%; HCV, 1%; HIV, 0.3%).

Results

The prevalence of HBV, HCV, and HIV was 2.4%, 1.4%, and 0.1%, respectively, in the 908 patients with IBD. Among the 581 patients with UC, 2.2% (12/541) had HBV, 1.7% (9/517) had HCV, and 0.2% (1/499) had HIV. Among the 327 patients with CD, 2.8% (8/288) had HBV, 0.7% (2/273) had HCV, and 0% (0/277) had HIV. One patient with CD had HBV and HCV coinfection. The prevalence of HBV, HCV, and HIV in patients with ITB was 5.9% (4/67), 1.8% (1/57), and 1.2% (1/84), respectively.

Conclusions

The prevalence of HBV, HCV, and HIV in north Indian patients with IBD is similar to the prevalence of these viruses in the general community. Nonetheless, the high risk of flare after immunosuppressive therapy mandates routine screening of patients with IBD for viral markers.

Citations

Citations to this article as recorded by  
  • ECCO consensus on management of inflammatory bowel disease in low- and middle-income countries
    Alaa El-Hussuna, Almuthe Christina Hauer, Tarkan Karakan, Valerie Pittet, Henit Yanai, Jalpa Devi, Jesus K Yamamoto-Furusho, Ali Reza Sima, Hailemichael Desalegn, Mutaz Idrees Sultan, Vishal Sharma, Hany Shehab, Lamya Mrabti, Natalia Queiroz, Anuraag Jena
    Journal of Crohn’s and Colitis.2026;[Epub]     CrossRef
  • Prevalence of viral hepatitis A and C in patients with inflammatory bowel disease: a nationwide population-based study in South Korea
    Jin Hwa Park, Sang Hyoung Park, Sang Pyo Lee, Kang Nyeong Lee, Hang Lak Lee, Oh Young Lee, Soorack Ryu, Junwon Go
    The Korean Journal of Internal Medicine.2026; 41(1): 95.     CrossRef
  • Brucellosis in a patient with Crohn's disease treated with infliximab: A case report
    Mansour Altuwaijri, Nasser Alkhraiji, Mosaab Almasry, Saad Alkhowaiter, Nuha Al Amaar, Ammar Alotaibi
    Arab Journal of Gastroenterology.2025; 26(1): 38.     CrossRef
  • Managing IBD Patients with Concomitant HIV Infection - a Systematic Review
    Hugo Sousa, Joana Barroso, Raquel Tavares, Joana Torres
    Current Gastroenterology Reports.2024; 26(1): 1.     CrossRef
  • Prevalence of hepatitis B virus and hepatitis C virus infection in patients with inflammatory bowel disease: a systematic review and meta-analysis
    Suprabhat Giri, Dhiraj Agrawal, Shivaraj Afzalpurkar, Sunil Kasturi, Amrit Gopan, Sridhar Sundaram, Aditya Kale
    Intestinal Research.2023; 21(3): 392.     CrossRef
  • Expert consensus on vaccination in patients with inflammatory bowel disease in Japan
    Takashi Ishige, Toshiaki Shimizu, Kenji Watanabe, Katsuhiro Arai, Koichi Kamei, Takahiro Kudo, Reiko Kunisaki, Daisuke Tokuhara, Makoto Naganuma, Tatsuki Mizuochi, Atsuko Murashima, Yuta Inoki, Naomi Iwata, Itaru Iwama, Sachi Koinuma, Hirotaka Shimizu, Ke
    Journal of Gastroenterology.2023; 58(2): 135.     CrossRef
  • Prevalence of viral hepatitis infection in India: A systematic review and meta-analysis
    Dhasarathi Kumar, Roshni M. Peter, Alex Joseph, Kalpana Kosalram, Harpreet Kaur
    Journal of Education and Health Promotion.2023;[Epub]     CrossRef
  • Frequency of hepatitis C virus infection in patients with pediatric inflammatory bowel disease: a cross-sectional study
    Sara Tarek, Ayman E. Eskander, Safa Meshaal, Eman Badr, Asmaa Abd El-Hakeem
    Egyptian Pediatric Association Gazette.2023;[Epub]     CrossRef
  • Pancreatic Disorders in Patients with Inflammatory Bowel Disease
    Marilia L. Montenegro, Juan E. Corral, Frank J. Lukens, Baoan Ji, Paul T. Kröner, Francis A. Farraye, Yan Bi
    Digestive Diseases and Sciences.2022; 67(2): 423.     CrossRef
  • Vaccination strategies for Korean patients with inflammatory bowel disease
    Yoo Jin Lee, Eun Soo Kim
    The Korean Journal of Internal Medicine.2022; 37(5): 920.     CrossRef
  • Viral Hepatitis in Patients with Inflammatory Bowel Disease
    Seung Hwan Shin, Sang Hyoung Park
    The Korean Journal of Gastroenterology.2022; 80(2): 51.     CrossRef
  • Involvement of HHV-4 (Epstein–Barr Virus) and HHV-5 (Cytomegalovirus) in Inflammatory Bowel Disease and Colorectal Cancer: A Meta-Analysis
    Luigi Marongiu, Sascha Venturelli, Heike Allgayer
    Cancers.2022; 14(20): 5085.     CrossRef
  • Prevalence of serological markers of hepatitis B in inflammatory bowel disease – Experience from a tertiary care centre in South India
    Amol Prabhakar Patil, Ebby George Simon, Amit Kumar Dutta, Anjilivelil Joseph Joseph, Reuben Thomas Kurien, Sudipta Dhar Chowdhury
    Tropical Doctor.2021; 51(3): 326.     CrossRef
  • Comorbidity before and after a diagnosis of inflammatory bowel disease
    Charles N. Bernstein, Zoann Nugent, Seth Shaffer, Harminder Singh, Ruth Ann Marrie
    Alimentary Pharmacology & Therapeutics.2021; 54(5): 637.     CrossRef
  • ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease
    T Kucharzik, P Ellul, T Greuter, J F Rahier, B Verstockt, C Abreu, A Albuquerque, M Allocca, M Esteve, F A Farraye, H Gordon, K Karmiris, U Kopylov, J Kirchgesner, E MacMahon, F Magro, C Maaser, L de Ridder, C Taxonera, M Toruner, L Tremblay, M Scharl, N
    Journal of Crohn's and Colitis.2021; 15(6): 879.     CrossRef
  • Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment
    Georgios Axiaris, Evanthia Zampeli, Spyridon Michopoulos, Giorgos Bamias
    World Journal of Gastroenterology.2021; 27(25): 3762.     CrossRef
  • Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia
    Rupa Banerjee, Partha Pal, Joyce Wing Yan Mak, Siew C Ng
    The Lancet Gastroenterology & Hepatology.2020; 5(12): 1076.     CrossRef
  • Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease
    Seong Jae Yeo, Hyun Seok Lee, Byung Ik Jang, Eun Soo Kim, Seong Woo Jeon, Sung Kook Kim, Kyeong Ok Kim, Yoo Jin Lee, Hyun Jik Lee, Kyung Sik Park, Yun Jin Jung, Eun Young Kim, Chang Heon Yang
    Intestinal Research.2018; 16(3): 400.     CrossRef
  • Inflammatory bowel disease is no longer a risk factor of viral hepatitis infection in Asia
    Eun Soo Kim
    Intestinal Research.2017; 15(1): 5.     CrossRef
  • 7,799 View
  • 55 Download
  • 19 Web of Science
  • 19 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP